Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC-Reference-Cited by-同舟云学术

Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC

Published:2021-12-29 Issue: Volume: Page:
ISSN:2366-004X
Container-title:Abdominal Radiology
language:en
Short-container-title:Abdom Radiol

Author:

Lewis Sara^ORCID,Cedillo Mario A.,Lee Karen M.,Bane Octavia,Hectors Stefanie,Ma Weiping,Wang Pei,Stocker Daniel,Morris Darrell V.,Pinato David,Sung Max,Marron Thomas,Schwartz Myron,Taouli Bachir

Publisher

Springer Science and Business Media LLC

Subject

Urology,Gastroenterology,Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Link

https://link.springer.com/content/pdf/10.1007/s00261-021-03386-0.pdf

Reference29 articles.

1. Singal, A.G., P. Lampertico, and P. Nahon, Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol, 2020. 72(2): p. 250-261.

2. Forner, A., et al., Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis, 2010. 30(1): p. 61-74.

3. Llovet, J.M., et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008. 359(4): p. 378-90.

4. Llovet, J.M., et al., Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol, 2018. 15(10): p. 599-616.

5. Cheng, A.L., et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009. 10(1): p. 25-34.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma;Scientific Reports;2024-08-28

2. Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma;Seminars in Liver Disease;2023-11

3. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice;The Lancet Gastroenterology & Hepatology;2023-08

4. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma;Journal of Liver Cancer;2023-03-31

5. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?;International Journal of Molecular Sciences;2023-01-31